 |
|
Short-term Menopausal Hormone Therapy for Symptom Relief
An Updated Decision Model
Nananda F. Col, MD, MPP, MPH;
Griffin Weber, MD, PhD;
Anne Stiggelbout, PhD;
John Chuo, MD;
Ralph D'Agostino, PhD;
Phaedra Corso, PhD
Arch Intern Med. 2004;164:1634-1640.
Background Hormone therapy (HT) provides the most effective relief of menopausal symptoms. This therapy is associated with a decreased risk of osteoporosis and colorectal cancer but increased risks of cardiovascular disease (CVD), venous thrombosis, and breast cancer. Our objective was to identify which women should benefit from short-term HT by exploring the trade-off between symptom relief and risks of inducing disease.
Methods A Markov model simulates the effect of short-term (2 years) estrogen and progestin HT on life expectancy and quality-adjusted life expectancy (QALE) among 50-year-old menopausal women with intact uteri, using findings from the Women's Health Initiative. Quality-of-life (QOL) utility scores were derived from the literature. We assumed HT-affected QOL only during perimenopause, when it reduced symptoms by 80%.
Results Among asymptomatic women, short-term HT was associated with net losses in life expectancy and QALE of 1 to 3 months, depending on CVD risk. Women with mild or severe menopausal symptoms gained 3 to 4 months or 7 to 8 months of QALE, respectively. Among women at low risk for CVD, HT extended QALE if menopausal symptoms lowered QOL by as little as 4%. Among women at elevated CVD risk, HT extended QALE only if symptoms lowered QOL by at least 12%.
Conclusions Hormone therapy is associated with losses in survival but gains in QALE for women with menopausal symptoms. Women expected to benefit from short-term HT can be identified by the severity of their menopausal symptoms and CVD risk.
From the Division of General Internal Medicine, Rhode Island Hospital, Brown Medical School, Providence (Dr Col); Harvard Medical School, Boston, Mass (Dr Weber); Leiden University Medical Center, Leiden, the Netherlands (Dr Stiggelbout); Brigham and Women's Hospital, Boston (Dr Chuo); Boston University, Boston (Dr D'Agostino); and Centers for Disease Control and Prevention, Atlanta, Ga (Dr Corso). The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Can Computerized Decision Support Help Patients Make Complex Treatment Decisions? A Randomized Controlled Trial of an Individualized Menopause Decision Aid
Col et al.
Med Decis Making 2007;27:585-598.
ABSTRACT
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists
Collins et al.
Eur Heart J 2007;28:2028-2040.
ABSTRACT
| FULL TEXT
Decision making at the fringe of evidence: take what you can get.
Col
Arch Intern Med 2006;166:389-390.
FULL TEXT
Common Adverse Effects of Short-term Hormone Therapy
Ohsfeldt
Arch Intern Med 2005;165:587-588.
FULL TEXT
Hormone Therapy: Making Decisions in the Face of Uncertainty
Peterson et al.
Arch Intern Med 2004;164:2308-2312.
FULL TEXT
Summary of Balancing Risks and Benefits
Obstet Gynecol 2004;104:128S-129S.
FULL TEXT
|
